Last edition
News about "amyotrophic lateral sclerosis "
Ractigen Therapeutics Doses First Patient in Phase I Clinical Trial for RAG-17 in SOD1-ALS
RAG-17 received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) in March 2023, followed by the FDA's clearance of its Investigational New Drug (IND) application.
Amyotrophic Lateral Sclerosis | 26/12/2024 | By Aishwarya
MTPA Signs Deal with Dewpoint to Advance Small Molecule Condensate Modulator
The collaboration focuses on developing a novel TDP-43 small molecule condensate modulator (c-mod) for amyotrophic lateral sclerosis (ALS), furthering MTPC's commitment to advancing innovation in ALS and central nervous system (CNS) diseases.
Amyotrophic Lateral Sclerosis | 19/12/2024 | By Aishwarya
Ractigen Therapeutics Secures FDA Orphan Drug Designation for RAG-21
RAG-21 is an siRNA therapy specifically designed to target FUS-ALS, one of the most aggressive subtypes of ALS.
Amyotrophic Lateral Sclerosis | 20/11/2024 | By Aishwarya
Gland Pharma Receives Nod from US FDA for Rare Muscle Disorder
Gland Pharma Ltd. has received approval from the US health regulator for its generic Edaravone injection to treat amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis | 08/05/2024 | By Aishwarya | 150
MTPA Presents Healthcare Resource Utilization Data in RADICAVA ORS at AMCP 2024
Mitsubishi Tanabe Pharma America, Inc. (MTPA) has recently presented one abstract on amyotrophic lateral sclerosis (ALS) at the Academy of Managed Care Pharmacy (AMCP) 2024 Annual Meeting.
Amyotrophic Lateral Sclerosis | 16/04/2024 | By Aishwarya
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy